(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 October 2011 (06.10.2011)

PCT

(10) International Publication Number
WO 2011/123507 A1

(51) **International Patent Classification**:
C07K 16/24 (2006.01) ***A61K 39/395*** (2006.01)

(21) **International Application Number**:
PCT/US2011/030469

(22) **International Filing Date**:
30 March 2011 (30.03.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

61/341,458	30 March 2010 (30.03.2010)	US
61/319,260	31 March 2010 (31.03.2010)	US

(71) **Applicant** *(for all designated States except US)*: **CENTOCOR ORTHO BIOTECH INC.** [US/US]; 800/850 Ridgeview Drive, Horsham, PA 19044 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **ALMAGRO, Juan, Carlos** [US/US]; 145 King Of Prussia Road, Radnor, PA 19087 (US). **BRANIGAN, Patrick** [US/US]; 145 King Of Prussia Road, Radnor, PA 19087 (US). **KANE, Colleen** [US/US]; 145 King Of Prussia Road, Radnor, PA 19087 (US). **STROHL, William** [US/US]; 145 King Of Prussia Road, Radnor, PA 19087 (US). **TAUDTE, Susann** [US/US]; 145 King Of Prussia Road, Radnor, PA 19087 (US). **TORNETTA, Mark** [US/US]; 145 King Of Prussia Road, Radnor, PA 19087 (US). **WHEELER, John** [US/US]; 145 King Of Prussia Road, Radnor, PA 19087 (US).

(74) **Agents**: **JOHNSON, Philip S.** et al.; Johnson & Johnson, 1 Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2011/123507 A1

(54) **Title**: HUMANIZED IL-25 ANTIBODIES

(57) **Abstract**: The present invention relates to target binding members (e.g., antibodies) that bind a specified epitope of human IL-25. The invention also relates to target binding members (e.g., antibodies) that comprise one or more humanized antibody VL domain sequences and bind IL-25. The invention further relates to compositions comprising target binding members (e.g., antibodies) that bind IL-25, methods of producing such target binding members, and uses of such target binding members for the treatment or prevention of diseases and conditions (e.g., asthma, inflammatory bowel disease).